 |
|
A Double-blind, Placebo-Controlled Trial of Testosterone Therapy for HIV-Positive Men With Hypogonadal Symptoms
Judith G. Rabkin, PhD, MPH;
Glenn J. Wagner, PhD;
Richard Rabkin, MD
Arch Gen Psychiatry. 2000;57:141-147.
Background The goal was to evaluate the efficacy of testosterone in alleviation of hypogonadal symptoms (diminished libido, depressed mood, low energy, and depleted muscle mass) in men with symptomatic human immunodeficiency virus illness.
Methods Seventy-four patients were enrolled in a double-blind, placebo-controlled 6-week trial with biweekly testosterone injections, followed by 12 weeks of open-label maintenance treatment. Major outcome measures were Clinical Global Impressions Scale ratings for libido, mood, energy, and erectile function; Hamilton Depression Rating Scale scores, and Chalder Fatigue Scale scores. Body composition changes were assessed with bioelectric impedance analysis.
Results Seventy men completed the 6-week trial. Response rates, defined as much or very much improved libido, were 74% (28/38) for patients randomized to testosterone, and 19% (6/32) for placebo-treated patients (P<.001). Of the 62 completers with fatigue at baseline, 59% (20/34) receiving testosterone and 25% (7/28) receiving placebo reported improved energy (P<.01). Among the 26 completers with an Axis I depressive disorder at baseline, 58% of the testosterone-treated patients reported improved mood compared with 14% of placebo-treated patients (Fisher exact test = .08). With testosterone treatment, average increase in muscle mass over 12 weeks was 1.6 kg for the whole group, and 2.2 kg for the 14 men with wasting at baseline. Improvement on all parameters was maintained during subsequent open-label treatment for up to 18 weeks.
Conclusion Testosterone is well tolerated and effective in the short-term treatment of symptoms of clinical hypogonadism in men with symptomatic human immunodeficiency virus illness, restoring libido and energy, alleviating depressed mood, and increasing muscle mass.
From the New York State Psychiatric Institute (Drs J. Rabkin and R. Rabkin), Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY (Drs J. Rabkin and R. Rabkin); and RAND Corporation, Santa Monica, Calif (Dr Wagner).
RELATED ARTICLES
Effects of Supraphysiologic Doses of Testosterone on Mood and Aggression in Normal Men: A Randomized Controlled Trial
Harrison G. Pope, Jr, Elena M. Kouri, and James I. Hudson
Arch Gen Psychiatry. 2000;57(2):133-140.
ABSTRACT
| FULL TEXT
Time Course of Effects of Testosterone Administration on Sexual Arousal in Women
Adriaan Tuiten, Jack Van Honk, Hans Koppeschaar, Coen Bernaards, Jos Thijssen, and Rien Verbaten
Arch Gen Psychiatry. 2000;57(2):149-153.
ABSTRACT
| FULL TEXT
Testosterone in Psychiatry: Risks and Benefits
William R. Yates
Arch Gen Psychiatry. 2000;57(2):155-156.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss
Knapp et al.
Am. J. Physiol. Endocrinol. Metab. 2008;294:E1135-E1143.
ABSTRACT
| FULL TEXT
Low Free Testosterone Concentration as a Potentially Treatable Cause of Depressive Symptoms in Older Men
Almeida et al.
Arch Gen Psychiatry 2008;65:283-289.
ABSTRACT
| FULL TEXT
Physiological Correlates of HIV-Related Fatigue
Barroso et al.
Clin Nurs Res 2008;17:5-19.
ABSTRACT
Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men.
Bloch et al.
Arch Gen Psychiatry 2006;63:450-456.
ABSTRACT
| FULL TEXT
Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) for Treatment of Nonmajor Depression in Patients With HIV/AIDS
Rabkin et al.
Am. J. Psychiatry 2006;163:59-66.
ABSTRACT
| FULL TEXT
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment{dagger}
Shafqat et al.
Ann Oncol 2005;16:1545-1550.
ABSTRACT
| FULL TEXT
Safety and Efficacy of Testosterone Gel 1% Augmentation in Depressed Men With Partial Response to Antidepressant Therapy
Orengo et al.
J Geriatr Psychiatry Neurol 2005;18:20-24.
ABSTRACT
The Effects of Pharmacologically Induced Hypogonadism on Mood in Healthy Men
Schmidt et al.
Arch Gen Psychiatry 2004;61:997-1004.
ABSTRACT
| FULL TEXT
Current Concepts in Anabolic-Androgenic Steroids
Evans
Am J Sports Med 2004;32:534-542.
ABSTRACT
| FULL TEXT
Increased Incidence of Diagnosed Depressive Illness in Hypogonadal Older Men
Shores et al.
Arch Gen Psychiatry 2004;61:162-167.
ABSTRACT
| FULL TEXT
Endocrinological disturbances in chronic obstructive pulmonary disease
Creutzberg and Casaburi
Eur Respir J 2003;22:76S-80s.
ABSTRACT
| FULL TEXT
Physiological and Psychological Markers Associated with HIV-Related Fatigue
Barroso et al.
Clin Nurs Res 2003;12:49-68.
ABSTRACT
Use and Effectiveness of Performance-Enhancing Substances
Boyce
Journal of Pharmacy Practice 2003;16:22-36.
ABSTRACT
Testosterone Gel Supplementation for Men With Refractory Depression: A Randomized, Placebo-Controlled Trial
Pope et al.
Am. J. Psychiatry 2003;160:105-111.
ABSTRACT
| FULL TEXT
Refractory Nonmotor Symptoms in Male Patients With Parkinson Disease Due to Testosterone Deficiency: A Common Unrecognized Comorbidity
Okun et al.
Arch Neurol 2002;59:807-811.
ABSTRACT
| FULL TEXT
Psychiatric Aspects of HIV Care
AIDS Clin Care 2001;2001:6-6.
FULL TEXT
Viruses in the Mammalian Male Genital Tract and Their Effects on the Reproductive System
Dejucq and Jegou
Microbiol. Mol. Biol. Rev. 2001;65:208-231.
ABSTRACT
| FULL TEXT
Testosterone's Effects Not Limited to Mood
Daly et al.
Arch Gen Psychiatry 2001;58:403-404.
FULL TEXT
Sexual Dysfunction and HIV Infection
AIDS Clin Care 2000;2000:1-1.
FULL TEXT
Testosterone in Psychiatry: Risks and Benefits
Yates
Arch Gen Psychiatry 2000;57:155-156.
FULL TEXT
|
